Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

116.09 +0.66 (+0.58%)

Streaming Delayed Price Updated: 11:47 AM EDT, Mar 17, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

99 100 Next >

Large Cap Biopharmaceutical Update: Mixed Performance As Tariffs Loom ↗

April 28, 2025

Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising...

Via Talk Markets

Topics ETFs Stocks / Equities

9 Health Care Stocks Whale Activity In Today's Session ↗

April 28, 2025

Via Benzinga

Why Is Summit Therapeutics Stock Trading Higher On Monday? ↗

April 28, 2025

Summit Therapeutics highlights China approval of Akeso's ivonescimab for NSCLC, with enrollment ongoing for Phase 3 HARMONi-7 trial.

Via Benzinga

Merck Germany Buys US Cancer Drugmaker SpringWorks Therapeutics For Around $4 Billion ↗

April 28, 2025

Merck & Company, Inc. (MRK) to acquire SpringWorks Therapeutics, Inc. (SWTX) for $47/share in cash, creating synergies for rare tumor treatments and immediate revenue growth.

Via Benzinga

Earnings Scheduled For April 24, 2025 ↗

April 24, 2025

Via Benzinga

Despite its impressive fundamentals,MERCK & CO. INC. (NYSE:MRK) remains undervalued. ↗

April 28, 2025

Discover MERCK & CO. INC., an undervalued stock. NYSE:MRK showcases solid financial health and profitability while maintaining an appealing valuation.

Via Chartmill

Pfizer (PFE) Reports Q1: Everything You Need To Know Ahead Of Earnings

April 28, 2025

Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting earnings tomorrow before market hours. Here’s what you need to know.

Via StockStory

Topics Government World Trade

KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

April 27, 2025

From Merck & Co., Inc.

Via Business Wire

2 Outstanding Dividend Stocks to Buy and Hold For 20 Years ↗

April 26, 2025

Via The Motley Fool

Topics Government World Trade

These S&P500 stocks are moving in today's session ↗

April 25, 2025

Curious about the top performers within the S&P500 index one hour before the close of the markets on Friday? Dive into the list of today's session's top gainers and losers for a comprehensive...

Via Chartmill

Merck Stays Confident On M&A Despite Market Uncertainty: Analyst ↗

April 25, 2025

Merck projects $200 million in tariff costs, boosts U.S. manufacturing plans, and continues M&A efforts amid external pressures and shifting market dynamics.

Via Benzinga

Topics World Trade

What's Going On With Summit Therapeutics Stock On Friday? ↗

April 25, 2025

Summit Therapeutics' partner Akeso received FDA approval for penpulimab-kcqx in NPC, while ivonescimab showed strong data in lung cancer trials.

Via Benzinga

Market Monitor April 25 ( Texas Instruments, Nvidia & Amazon UP, IBM, PepsiCo & Comcast DOWN) ↗

April 25, 2025

Wall Street Rallies Again: Tech Leads the Charge, Alphabet Shines After-Hours

Via Chartmill

Merck (MRK) Q1 2025 Earnings Call Transcript ↗

April 24, 2025

Via The Motley Fool

Topics Earnings World Trade

Halozyme Sues Merck Over Subcutaneous Keytruda Formulation, Seeks Injunctive Relief ↗

April 24, 2025

Halozyme said that it believes the subcutaneous formulation of Merck's cancer medicine Keytruda infringes multiple patents that Halozyme filed beginning in 2011 to protect its groundbreaking MDASE...

Via Stocktwits

Topics Intellectual Property Lawsuit

Merck's Q1 Earnings Beat Wall Street, Adjusts 2025 Profit Outlook As Tariffs May Result In Incremental Cost Of $200 Million ↗

April 24, 2025

Merck posted Q1 adjusted EPS of $2.22 and revenue of $15.53 billion, beating estimates while revising full-year guidance amid tariff-related cost pressure.

Via Benzinga

Topics Earnings

Wall Street Rally Extends Into Third Day: What's Driving Markets Thursday? ↗

April 24, 2025

U.S. equities are pushing higher for a third straight session, eyeing the longest winning streak since the Trump tariff announcement on April 2, as optimism over corporate earnings and easing trade...

Via Benzinga

Topics Government World Trade

Merck & Co. Reports Better Than Expected Results For First-Quarter 2025 ↗

April 24, 2025

Merck's Q1 2025 results show a slight decrease in total sales but highlight growth in key segments.

Via Talk Markets

Topics Stocks / Equities

Durable Goods Orders Jump 9.2% In March, But One Category Tells The Real Story ↗

April 24, 2025

US durable goods orders surged in March, but with a mixed picture. Transportation equipment led the gain, while other sectors showed minimal growth or decline.

Via Benzinga

Merck Reports Strong Q1 Earnings But Downgrades Full-Year Guidance: Retail Sentiment Brightens ↗

April 24, 2025

Merck estimates that the impact of tariffs implemented to date will result in incremental costs of approximately $200 million.

Via Stocktwits

Topics Government World Trade

Merck’s (NYSE:MRK) Q1 Sales Beat Estimates

April 24, 2025

Global pharmaceutical company Merck (NYSE:MRK) beat Wall Street’s revenue expectations in Q1 CY2025, but sales fell by 1.6% year on year to $15.53 billion. The company expects the full year’s revenue...

Via StockStory

Topics Artificial Intelligence Earnings Intellectual Property

Gardasil Sales Decline — Again. Can Dow Jones Stock Merck Take The Hit? ↗

April 24, 2025

This is the third quarter of accelerating sales declines amid slow demand in China for Gardasil vaccines.

Via Investor's Business Daily

Topics Earnings Government Stocks

Merck Announces First-Quarter 2025 Financial Results

April 24, 2025

From Merck & Co., Inc.

Via Business Wire

Why Is Summit Therapeutics Stock Soaring On Wednesday? ↗

April 23, 2025

Summit and Akeso report Phase 3 success as ivonescimab shows PFS gains in NSCLC trial, with new studies and collaborations underway.

Via Benzinga

Merck Stock Slumps Ahead Of Q1 Earnings: Can Bulls Find Relief In Buying Pressure? ↗

April 23, 2025

Merck & Co reports Q1 earnings on Thursday with EPS of $2.14 and revenue of $15.33B expected. Despite a 38.04% drop in stock over past year, analysts see ~30% upside potential.

Via Benzinga

BioNTech Surges On Summit's Coattails. But Can They Take On Merck? ↗

April 23, 2025

BioNTech is on the rise after Summit Therapeutics unveiled promising results for its PD-1- and VEGF-blocking drug.

Via Investor's Business Daily

Merck (MRK) Reports Q1: Everything You Need To Know Ahead Of Earnings

April 23, 2025

Global pharmaceutical company Merck (NYSE:MRK) will be reporting results tomorrow before market hours. Here’s what to expect.

Via StockStory

Gilead Cancer Drug Combined With Merck's Drug Effective In Difficult To Treat Type Of Breast Cancer ↗

April 21, 2025

Gilead's Trodelvy and Merck's Keytruda improved progression-free survival in PD-L1+ metastatic TNBC in a Phase 3 trial with no new safety concerns.

Via Benzinga

Gilead Announces Positive Results From Trodelvy-Keytruda Combo Study For Breast Cancer: But Retail’s Unmoved ↗

April 21, 2025

Triple-negative breast cancer accounts for approximately 15% of all breast cancers and has a higher chance of recurrence.

Via Stocktwits

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields ↗

April 21, 2025

Via Benzinga

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.